Reagents ABI buys Ambion's reagent biz for $273 million | GenomeWeb

Ambion has been around for 17 years, but the decision to sell it came down to 30 seconds, recalls Bruce Leander, president of the Austin, Texas-based company. Leander says that last July, Ambion founder Matt Winkler stepped into his office and was mulling over the idea of starting up a diagnostic company, and wondering how to get funding for it. "He said, ‘What do you think about selling Ambion?'" Leander says. "I thought about it for half a minute and I said, ‘I think that's a great idea.'"

 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.